Stockreport
Vertex Pharma’s three-drug combinations improve breathing in some cystic fibrosis patients [CNBC]
Last vertex pharmaceuticals, inc earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
PDF
Vertex Pharmaceuticals said Tuesday that its three-drug cocktails improved a measure of lung function in patients with cystic fibrosis by 9.6 percentage points or more, surpassing Wall Street's expectations and setting the company up to advance a medicine to treat thousands more patients with the disease. The Boston-based biotech company is testing multiple combination regimens to find the best cocktail for a majority of patients with cystic fibrosis. Vertex has brought to market medicines for genetic forms of the disease affecting about 30,000 of the 75,000 people with CF worldwide; the majority of patients, though, still have no approved treatment options that target the disease's underlying cause. Cystic fibrosis is a rare, genetic disease that causes mucus to build up in the lungs and other organs, leading to infections, damage and respiratory failure. It's driven by mutations in a gene known as CFTR, and because different mutations manifest in slightly different wa
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- Moderna Aims To Revolutionize Modern Medicine With A New Class Of Drugs [Seeking Alpha][Seeking Alpha]
- Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases[Business Wire]
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.[MarketBeat]
- Vertex Pharmaceuticals Incorporated 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha][Seeking Alpha]
- 5 Things You Need to Know From Vertex Pharmaceuticals' Q1 Earnings Update [The Motley Fool][The Motley Fool]
- More
VRTX
SEC Filings
SEC Filings
- 5/17/19 - Form 4
- 5/17/19 - Form 4
- 5/17/19 - Form 4
- VRTX's page on the SEC website
- More